Literature DB >> 29644084

Primary microcephaly caused by novel compound heterozygous mutations in ASPM.

Nobuhiko Okamoto1, Tomohiro Kohmoto2, Takuya Naruto2, Kiyoshi Masuda2, Issei Imoto2.   

Abstract

Autosomal recessive primary microcephaly (microcephaly primary hereditary, MCPH) is a genetically heterogeneous rare developmental disorder that is characterized by prenatal onset of abnormal brain growth, which leads to intellectual disability of variable severity. We report a 5-year-old male who presented with a severe form of primary microcephaly. Targeted panel sequencing revealed compound heterozygous truncating mutations of the abnormal spindle-like microcephaly-associated (ASPM) gene, which confirmed the MCPH5 diagnosis. A novel NM_018136.4: c.9742_9745del (p.Lys3248Serfs*13) deletion mutation was identified.

Entities:  

Year:  2018        PMID: 29644084      PMCID: PMC5885039          DOI: 10.1038/hgv.2018.15

Source DB:  PubMed          Journal:  Hum Genome Var        ISSN: 2054-345X


Autosomal recessive primary microcephaly (microcephaly primary hereditary, MCPH, MIM#251200) is a genetically heterogeneous developmental disorder that is characterized by prenatal onset of abnormal brain growth, resulting in a reduced brain volume, which is indirectly measured as an occipitofrontal circumference (OFC) that is equal to or greater than 2 standard deviations (SDs) and 3 SDs below the age- and sex-matched means at birth and 6 months, respectively. These physical abnormalities lead to varying degrees of non-progressive intellectual disability in the absence of any significant neurological deficit.[1] Eighteen MCPH loci are implicated in MCPH (MCPH1-18). Mutations of abnormal spindle-like microcephaly-associated (ASPM) gene (MIM#605481) are the most common cause of MCPH accounting for up to 40% in consanguineous and non-consanguineous families,[2] followed in frequency by mutations in WDR62. The phenotypic similarity between patients with MCPH-causing genes is remarkable.[3,4] Therefore, whole-exome sequencing or targeted panel sequencing (TPS) as a genetic screening technique is mandatory to delineate the etiology and obtain the proper prenatal diagnosis. We report a severe form of primary microcephaly exhibiting compound heterozygous ASPM mutations that included a novel deletion mutation. The patient was a 5-year-old male who was the first child of Japanese non-consanguineous parents. Microcephaly was noted prenatally on ultrasonography. He was delivered at 38 weeks of gestation, with a birth weight of 2058 g (−2.3 SD), body length of 43 cm (−2.3 SD) and OFC of 27 cm (−4.2 SD). He exhibited hypertonicity, opisthotonic posture and sleep disturbance. Trembling was noted in his body and neck. Brain magnetic resonance imaging (MRI) revealed a global reduction in the size of his cerebral structures, including the cortex and white matter, simplified gyral pattern and enlarged lateral ventricle with clear laterality (Figure 1a). Delayed motor development was marked from the infantile period. The patient sat with support at 1 year of age and began to walk independently at 3 years of age. He spoke incohesive words and exhibited a severe intellectual disability. His recognition and ability to communicate with others developed slowly. Routine laboratory investigations and metabolic surveys revealed normal results. Standard karyotyping and array-based comparative genomic hybridization using peripheral blood revealed no abnormalities. His body weight at 8 years of age was 12.5 kg (−1.8 SD), height was 90 cm (−3.0 SD) and OFC was 41.5 cm (−5.2 SD). Craniofacial dysmorphic features, including up-slanting palpebral fissures, epicanthus, high-arched palate and micrognathism, were noted. The clinical picture was typical of primary microcephaly, particularly MCPH. However, TPS with a panel of multiple potential disease-causing genes was used as the genetic screening test because of the absence of parental consanguinity.
Figure 1

(a) Brain MRI in the proband at 5 years of age. Axial (left) and sagittal (right) T1-weighted images reveal a global reduction in the size of the cerebral structures, including the cortex and white matter, simplified gyral pattern, enlarged lateral ventricle and fully formed but diffusely thin corpus callosum. Notably, the right side is more remarkably affected than the left side. The sloping of the forehead reflects a severe decrease in the cranial-to-facial proportions. (b) Partial sequence chromatograms around codons 2595 and 3248 on exons 18 and 24, respectively, of ASPM in the patient and his parents. Red boxes denote deleted bases, and red arrows denote the start sites of heterozygous sequences due to these deletions. DNA and corresponding amino acid sequences of the wild-type and mutant ASPM alleles are also shown.

Informed consent was obtained from the parents, and molecular diagnosis was performed using genomic DNA extracted from the patient’s blood. The ethics committees of Tokushima University and Osaka Medical Center and Research Institute for Maternal and Child Health approved the study. The TruSight One Sequencing Panel (Illumina, San Diego, CA, USA) was used with an MiSeq sequencer (Illumina), followed by analysis using our pipeline for NGS data as described previously[5] with a minor modification of a software update specific to the bioinformatics pipeline.[6] Sequence variants with higher allele frequencies (i.e., >0.01) in the following databases were excluded to identify presumably pathogenic single nucleotide variants: 1000 Genomes Project database (http://www.1000genomes.org), National Heart, Lung, and Blood Institute Grand Opportunity (NHLBI GO) Exome Sequencing Project (ESP6500, http://evs.gs.washington.edu/EVS), Human Genetic Variation Database (http://www.genome.med.kyoto-u.ac.jp/SnpDB) and integrative Japanese Genome Variation Database (iJGVD, https://ijgvd.megabank.tohoku.ac.jp). Copy-number variation analysis using TPS data was also performed as described previously.[6,7] These analyses detected two different 2- and 4-nucleotide deletions in exons 18 and 24 of the ASPM gene, namely, [NM_018136.4(ASPM_v001)], c.7782_7783del and c.9742_9745del, respectively, which caused reading frameshifts that ended with premature stop codons, p.Lys2595Serfs*6 and p.Lys3248Serfs*13, respectively. Sanger sequencing confirmed these deletions. The patient’s father and mother were heterozygous carriers of the c.7782_7783del and c.9742_9745del variants, respectively, which suggested the presence of these variations in the patient in a compound heterozygous state (Figure 1b). c.7782_7783del was present in the Human Gene Mutation Database (HGMD, Professional 2017.4, http://www.hgmd.org/) and ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/) as a pathogenic variant, but c.9742_9745del was not present in any database. No other possibly pathogenic variants or gross deletions were detected in the coding regions of other MCPH-related genes in the panel for TPS (data not shown). The patient was diagnosed with MCPH5 caused by one known and one novel deletion of ASPM in a compound heterozygous state based on the results of this molecular diagnosis and re-evaluation of the affected patient’s clinical features. The ASPM protein plays a crucial role in the maintenance of the cleavage plane orientation, which allows for the symmetric proliferative division of neuroepithelial cells during brain development.[8] A total of 167 ASPM pathogenic variants have been reported in cases with microcephaly in HGMD professional 2017.4. Most of these mutations are nonsense (69 variants), frameshift (small deletions and insertions, 79 variants) or splice-site mutations (15 variants), which are predicted to result in unstable RNA that is degraded by nonsense-mediated RNA decay (NMD) or truncated protein synthesis.[1-4] Therefore, most of the pathogenic variations of ASPM that are responsible for microcephaly reduce protein synthesis or produce partially or wholly non-functional short proteins. However, few experiments have verified this hypothesis.[4] The mutations were spread throughout the coding sequence of the ASPM gene, with no apparent hotspots, and there were no clear cut genotype–phenotype correlations between the head size centile, degree of intellectual disability or presence of epileptic fits and mutation type or position within the gene,[2] which suggests that NMD is the major mechanism through which ASPM gene mutations cause reduced fetal brain growth and result in MCPH5.[9,10] However, mice homozygously expressing truncated forms of ASPM similar to ASPM mutants that cause microcephaly in humans exhibit mild microcephaly associated with a reduced relative brain weight and cortical thickness, likely due to a reduced number of neural stem cells.[11] Therefore, the precise mechanisms that underlie the microcephaly caused by ASPM mutations in humans are not known.[4]

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
  11 in total

1.  Autosomal recessive primary microcephaly due to ASPM mutations: An update.

Authors:  Pascaline Létard; Séverine Drunat; Yoann Vial; Sarah Duerinckx; Anais Ernault; Daniel Amram; Stéphanie Arpin; Marta Bertoli; Tiffany Busa; Berten Ceulemans; Julie Desir; Martine Doco-Fenzy; Siham Chafai Elalaoui; Koenraad Devriendt; Laurence Faivre; Christine Francannet; David Geneviève; Marion Gérard; Cyril Gitiaux; Sophie Julia; Sébastien Lebon; Toni Lubala; Michèle Mathieu-Dramard; Hélène Maurey; Julia Metreau; Sanaa Nasserereddine; Mathilde Nizon; Geneviève Pierquin; Nathalie Pouvreau; Clothilde Rivier-Ringenbach; Massimiliano Rossi; Elise Schaefer; Abdelaziz Sefiani; Sabine Sigaudy; Yves Sznajer; Yusuf Tunca; Sophie Guilmin Crepon; Corinne Alberti; Monique Elmaleh-Bergès; Brigitte Benzacken; Bernd Wollnick; C Geoffrey Woods; Anita Rauch; Marc Abramowicz; Vincent El Ghouzzi; Pierre Gressens; Alain Verloes; Sandrine Passemard
Journal:  Hum Mutat       Date:  2018-01-16       Impact factor: 4.878

2.  Mutations in mouse Aspm (abnormal spindle-like microcephaly associated) cause not only microcephaly but also major defects in the germline.

Authors:  Jeremy N Pulvers; Jarosław Bryk; Jennifer L Fish; Michaela Wilsch-Bräuninger; Yoko Arai; Dora Schreier; Ronald Naumann; Jussi Helppi; Bianca Habermann; Johannes Vogt; Robert Nitsch; Attila Tóth; Wolfgang Enard; Svante Pääbo; Wieland B Huttner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

3.  Protein-truncating mutations in ASPM cause variable reduction in brain size.

Authors:  Jacquelyn Bond; Sheila Scott; Daniel J Hampshire; Kelly Springell; Peter Corry; Marc J Abramowicz; Ganesh H Mochida; Raoul C M Hennekam; Eamonn R Maher; Jean-Pierre Fryns; Abdulrahman Alswaid; Hussain Jafri; Yasmin Rashid; Ammar Mubaidin; Christopher A Walsh; Emma Roberts; C Geoffrey Woods
Journal:  Am J Hum Genet       Date:  2003-10-21       Impact factor: 11.025

4.  ASPM is a major determinant of cerebral cortical size.

Authors:  Jacquelyn Bond; Emma Roberts; Ganesh H Mochida; Daniel J Hampshire; Sheila Scott; Jonathan M Askham; Kelly Springell; Meera Mahadevan; Yanick J Crow; Alexander F Markham; Christopher A Walsh; C Geoffrey Woods
Journal:  Nat Genet       Date:  2002-09-23       Impact factor: 38.330

5.  Molecular and phenotypic spectrum of ASPM-related primary microcephaly: Identification of eight novel mutations.

Authors:  Mohamed S Abdel-Hamid; Manal F Ismail; Hebatallh A Darwish; Laila K Effat; Maha S Zaki; Ghada M H Abdel-Salam
Journal:  Am J Med Genet A       Date:  2016-06-02       Impact factor: 2.802

Review 6.  Autosomal Recessive Primary Microcephaly (MCPH): clinical manifestations, genetic heterogeneity and mutation continuum.

Authors:  Saqib Mahmood; Wasim Ahmad; Muhammad J Hassan
Journal:  Orphanet J Rare Dis       Date:  2011-06-13       Impact factor: 4.123

7.  A novel PTCH1 mutation in a patient with Gorlin syndrome.

Authors:  Nana Okamoto; Takuya Naruto; Tomohiro Kohmoto; Takahide Komori; Issei Imoto
Journal:  Hum Genome Var       Date:  2014-11-13

8.  Detection of 1p36 deletion by clinical exome-first diagnostic approach.

Authors:  Miki Watanabe; Yasunobu Hayabuchi; Akemi Ono; Takuya Naruto; Hideaki Horikawa; Tomohiro Kohmoto; Kiyoshi Masuda; Ryuji Nakagawa; Hiromichi Ito; Shoji Kagami; Issei Imoto
Journal:  Hum Genome Var       Date:  2016-05-12

9.  The molecular landscape of ASPM mutations in primary microcephaly.

Authors:  A K Nicholas; E A Swanson; J J Cox; G Karbani; S Malik; K Springell; D Hampshire; M Ahmed; J Bond; D Di Benedetto; M Fichera; C Romano; W B Dobyns; C G Woods
Journal:  J Med Genet       Date:  2008-11-21       Impact factor: 6.318

10.  A novel missense mutation of COL5A2 in a patient with Ehlers-Danlos syndrome.

Authors:  Miki Watanabe; Ryuji Nakagawa; Takuya Naruto; Tomohiro Kohmoto; Ken-Ichi Suga; Aya Goji; Shoji Kagami; Kiyoshi Masuda; Issei Imoto
Journal:  Hum Genome Var       Date:  2016-09-15
View more
  3 in total

1.  Normal early development in siblings with novel compound heterozygous variants in ASPM.

Authors:  Taro Moriwaki; Narutoshi Yamazaki; Tetsumin So; Motomichi Kosuga; Osamu Miyazaki; Yoko Narumi-Kishimoto; Tadashi Kaname; Gen Nishimura; Torayuki Okuyama; Yasuyuki Fukuhara
Journal:  Hum Genome Var       Date:  2020-01-06

2.  [Expression of ASPM in Lung Adenocarcinoma and Its Relationship with Development and Prognosis].

Authors:  Junjie Wang; Zhenyu He; Renhui Duan
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-01-20

3.  An update of pathogenic variants in ASPM, WDR62, CDK5RAP2, STIL, CENPJ, and CEP135 underlying autosomal recessive primary microcephaly in 32 consanguineous families from Pakistan.

Authors:  Sajida Rasool; Jamshaid Mahmood Baig; Abubakar Moawia; Ilyas Ahmad; Maria Iqbal; Syeda Seema Waseem; Maria Asif; Uzma Abdullah; Ehtisham Ul Haq Makhdoom; Emrah Kaygusuz; Muhammad Zakaria; Shafaq Ramzan; Saif Ul Haque; Asif Mir; Iram Anjum; Mehak Fiaz; Zafar Ali; Muhammad Tariq; Neelam Saba; Wajid Hussain; Birgit Budde; Saba Irshad; Angelika Anna Noegel; Stefan Höning; Shahid Mahmood Baig; Peter Nürnberg; Muhammad Sajid Hussain
Journal:  Mol Genet Genomic Med       Date:  2020-07-17       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.